Patents Represented by Attorney Manisha A. Desai
-
Patent number: 7320994Abstract: This application relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and its use as an inhibitor of the NK-1 subtype of tachykinin receptors, as well as a process for its preparation and intermediates therefor.Type: GrantFiled: April 22, 2003Date of Patent: January 22, 2008Assignee: Eli Lilly and CompanyInventors: Albert Kudzovi Amegadzie, Kevin Matthew Gardinier, Erik James Hembre, Jian Eric Hong, Louis Nickolaus Jungheim, Brian Stephen Muehl, David Michael Remick, Michael Alan Robertson, Kenneth Allen Savin
-
Patent number: 7179804Abstract: The present invention relates to selective NK-1 receptor antagonists of Formula (I); or a pharmaceutically acceptable salt thereof, for the treatment of disorders associated with an excess of tachykininsType: GrantFiled: April 22, 2003Date of Patent: February 20, 2007Assignee: Eli Lilly and CompanyInventors: Albert Kudzovi Amegadzie, Kevin Matthew Gardinier, Erik James Hembre, Jian Eric Hong, Louis Nickolaus Jungheim, Michael Alan Robertson, Kenneth Allen Savin
-
Patent number: 7098192Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided. Methods for treatment of diseases, particularly inflammatory diseases and cancers, associated with overexpression or constitutive activation of STAT3 or insufficient apoptosis are also provided.Type: GrantFiled: February 6, 2004Date of Patent: August 29, 2006Assignee: Isis Pharmaceuticals, Inc.Inventor: James G. Karras
-
Patent number: 6869957Abstract: This invention provides a novel series of non-peptidyl compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.Type: GrantFiled: September 23, 2003Date of Patent: March 22, 2005Assignee: Eli Lilly and CompanyInventors: Sung Y. Cho, Thomas A. Crowell, Bruce D. Gitter, Philip A. Hipskind, J. Jeffry Howbert, Joseph H. Krushinski, Jr., Karen L. Lobb, Brian S. Muehl, James A. Nixon
-
Patent number: 6844338Abstract: A pharmaceutical compound of the formula (I) in which R1 and R2 are each hydrogen or C1-6 alkyl, R3 is —SR10, —SOR10, —SO2R10, —COR10, —CH2OH or —CONHR11, where R10 is C1-6 alkyl and R11 is hydrogen or C1-6 alkyl, R4, R5, R6 and R7 are each hydrogen or C1-6alkyl, provided that at least one of R4, R5, R6 and R7 is C1-6alkyl, R8 and R9 are each hydrogen, halo, C1-6 alkyl or cyano, n is 0 or 1 and m is 2 or 3, x is a (a) or (b), and y is (c) or (d), wherein R12 and R13 are each hydrogen, C1- alkyl, cyclopropyl or cyclopropyl-C1-6 alkyl; and salts thereof.Type: GrantFiled: May 4, 2001Date of Patent: January 18, 2005Assignee: Eli Lilly and CompanyInventors: John Fairhurst, Peter Gallagher
-
Patent number: 6727255Abstract: This invention provides a novel series of non-peptidyl compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.Type: GrantFiled: June 5, 1995Date of Patent: April 27, 2004Assignee: Eli Lilly and CompanyInventors: Sung Y. Cho, Thomas A. Crowell, Bruce D. Gitter, Philip A. Hipskind, J. Jeffry Howbert, Joseph H. Krushinski, Jr., Karen L. Lobb, Brian S. Muehl, James A. Nixon
-
Patent number: 6403577Abstract: This invention provides a novel series of non-peptidyl compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.Type: GrantFiled: November 17, 1993Date of Patent: June 11, 2002Assignee: Eli Lilly and CompanyInventors: Sung Y. Cho, Thomas A. Crowell, Bruce D. Gitter, Philip A. Hipskind, J. Jeffry Howbert, Joseph H. Krushinski, Jr., Karen L. Lobb, Brian S. Muehl, James A. Nixon
-
Patent number: 6358994Abstract: This invention provides compounds of the Formula I: which are useful as tachykinin receptor antagonists. This invention also provides methods employing these compounds, as well as pharmaceutical formulations comprising these compounds.Type: GrantFiled: January 27, 2000Date of Patent: March 19, 2002Assignee: Eli Lilly and CompanyInventors: James E Fritz, Philip A Hipskind, Stephen W Kaldor, Karen L Lobb, James A Nixon
-
Patent number: 6358971Abstract: The present invention relates to compounds of Formula (I) below, which inhibit the growth of picornaviruses, Hepatitus viruses, enteroviruses, cardioviruses, polioviruses, coxsackieviruses of the A and B groups, echo virus and Mengo virus. wherein: A is phenyl, pyridyl, substituted phenyl, substituted pyridyl, or benzyl; R is hydrogen, COR4, or COCF3; X is N—OH, O, or CHR1; R1 is hydrogen, halo, CN, C1-C4 alkyl, —C≡CH, CO(C1-C4 alkyl), CO2(C1-C4 alkyl), or CONR2R3; R2 and R3 are independently hydrogen or C1-C4 alkyl; A′ is hydrogen, halo, C1-C6 alkyl, benzyl, naphthyl, thienyl, furyl, pyridyl, pyrollyl, COR4, S(O)nR4, or a group of the formula R4 is C1-C6 alkyl, phenyl, or substituted phenyl; n is 0, 1, or 2; R5 is independently at each occurrence hydrogen or halo; m is 1, 2, 3, or 4; and R6 is hydrogen, halo, CF3, OH, CO2H, NH2, NO2, CONHOCH3, C1-C4 alkyl, or CO2(C1-C4 alkyl), C1-C4 alkoxy; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 4, 2000Date of Patent: March 19, 2002Assignee: Eli Lilly and CompanyInventors: Jesus Ezquerra-Carrera, Joseph Michael Gruber, Chafiq Hamdouchi Hamdouchi, Richard Elmer Holmes, Wayne Alfred Spitzer
-
Patent number: 6339094Abstract: This invention provides a series of substituted propanamines useful as tachykinin receptor antagonists. This invention also provides methods employing these substituted propanamines as well as pharmaceutical formulations comprising these compounds.Type: GrantFiled: January 27, 2000Date of Patent: January 15, 2002Assignee: Eli Lilly and CompanyInventors: James E Fritz, Philip A Hipskind, Stephen W Kaldor, Karen L Lobb, James A Nixon
-
Patent number: 6329366Abstract: A pharmaceutical compound of the formula in which R1 and R2 are each hydrogen, halo, cyano or methyl, the dotted line represents an optional double bond, where R4 and R5 are each hydrogen, C1-6 alkyl, cyclopropyl or cyclopropyl-C1-6 alkyl, n is 0 or 1, and R3 is —SR6, —SOR6, —SO2R6, —COR6, —CH2OH or —CONHR7, where R6 is C1-6 alkyl and R7 is hydrogen or C1-6 alkyl; provided that when one of R1 and R2 is hydrogen and the other is fluoro, R4 and R5 are each hydrogen or C1-6 alkyl, and n is 0, then R3 is not —COR6 or —CONHR7; and salts thereof.Type: GrantFiled: November 18, 1999Date of Patent: December 11, 2001Assignee: Eli Lilly and Company LimitedInventors: John Fairhurst, Peter Thaddeus Gallagher, Martin Victor Miles
-
Patent number: 6255494Abstract: This invention provides a series of substituted benzimidazoles which are useful in treating or preventing a condition associated with an excess of neuropeptide Y. This invention also provides methods employing these substituted benzimidazoles as well as pharmaceutical formulations with comprise as an active ingredient one or more of these compounds.Type: GrantFiled: January 9, 1997Date of Patent: July 3, 2001Assignee: Eli Lilly and CompanyInventors: Thomas Charles Britton, Robert Frederick Bruns, Jr., Buddy Eugene Cantrell, Philip Arthur Hipskind, Karen Lynn Lobb, James Arthur Nixon, Paul Leslie Ornstein, Edward C. R. Smith, Hamideh Zarrinmayeh, Dennis Michael Zimmerman, Anne Marie Nunes, James Jeffry Howbert
-
Patent number: 6245761Abstract: This invention provides a series of substituted indoles which are useful in treating or preventing a condition associated with an excess of neuropeptide Y. This invention also provides the novel substituted indoles as well as pharmaceutical formulations with comprise as an active ingredient one or more of these substituted indoles.Type: GrantFiled: August 29, 1996Date of Patent: June 12, 2001Assignee: Eli Lilly and CompanyInventors: Thomas C. Britton, Robert F. Bruns, Jr., Donald R. Gehlert, Philip A. Hipskind, Karen L. Lobb, James A. Nixon, Paul L. Ornstein, Edward C. R. Smith, Hamideh Zarrinmayeh, Dennis M. Zimmerman
-
Patent number: 6242251Abstract: This invention describes a novel rhesus receptor having affinity for neuropeptide Y, pancreatic polypeptide, and peptide YY. This invention also encompasses nucleic acids encoding this receptor, or a fragment thereof, as well as methods employing this receptor and the nucleic acid compounds.Type: GrantFiled: March 18, 1998Date of Patent: June 5, 2001Assignee: Eli Lilly and CompanyInventors: Melvyn Baez, Peiyi Yang
-
Patent number: 6239144Abstract: The present invention provides methods of treating or preventing conditions associated with a lack of parathyroid hormone comprising administering to a mammal in need thereof an effective amount of a compound having activity as a tachykinin receptor antagonist. In a most preferred embodiment the present invention provides methods of increasing bone growth in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound having activity as a tachykinin receptor antagonist. Another embodiment of this invention provides methods of treating hyperparathyroidism in a mammal comprising administering to a mammal in need thereof an effective amount of a compound having activity as a tachykinin receptor antagonist.Type: GrantFiled: May 27, 1999Date of Patent: May 29, 2001Assignee: Eli Lilly and CompanyInventors: Rachelle J Galvin, Bruce D Gitter
-
Patent number: 6175013Abstract: This invention provides a series of substituted 2-imidazolines which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these compounds.Type: GrantFiled: June 10, 1994Date of Patent: January 16, 2001Assignee: Eli Lilly and CompanyInventors: Philip A. Hipskind, J. Jeffry Howbert, Brian S. Muehl
-
Patent number: 6166040Abstract: Pharmaceutical compounds of the formula: ##STR1## in which n is 1 to 6, m is 1 or 2 and p is 1 or 2, R.sup.1 and R.sup.2 are each hydrogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, HO--C.sub.1-4 alkyl, C.sub.1-4 alkoxy-C.sub.1-4 alkyl, C.sub.1-4 alkylthio, halo, optionally substituted phenyl, optionally substituted phenyl-C.sub.1-4 alkyl, or R.sup.1 and R.sup.2 together with the carbon atom to which they are attached form a C.sub.3-6 cycloalkyl group, >C.dbd.O, C.dbd.NOR' where R' is hydrogen or C.sub.1-4 alkyl,R.sup.3, R.sup.4 and R.sup.5 are each hydrogen, halo, nitro, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 alkyl-CO--, where m is 0, 1 or 2, R'R"N--SO.sub.2 --, --COOR', --CONR'R", --NR'R", --N(OR')COOR", --COR', --NHSO.sub.2 R', where R' and R' are each hydrogen or C.sub.1-4 alkyl,R.sup.6 and R.sup.7 are each hydrogen or C.sub.1-4 alkyl,X is oxygen or sulphur,the dotted line represents an optional double bond, and the fluorine atom is attached at the 6- or 7-position; and salts thereof.Type: GrantFiled: May 11, 1999Date of Patent: December 26, 2000Assignee: Eli Lilly and Company LimitedInventors: John Fairhurst, Peter Thaddeus Gallagher, Martin Victor Miles, William Martin Owton, Colin William Smith
-
Patent number: 6103524Abstract: This invention describes a novel human glutamate receptor, designated mGluR6. This invention also encompasses nucleic acids encoding this receptor, or a fragment thereof, as well as methods employing this receptor and the nucleic acid compounds.Type: GrantFiled: August 30, 1998Date of Patent: August 15, 2000Assignee: Eli Lilly and CompanyInventors: Rama Moorthy Belagaje, Su Wu
-
Patent number: 6087154Abstract: This invention describes a rhesus receptor, designated the rhesus Y1 receptor, having affinity for neuropeptide Y, pancreatic polypeptide, and peptide YY. This invention also encompasses nucleic acids encoding this receptor, or a fragment thereof, as well as methods employing this receptor and the nucleic acid compounds.Type: GrantFiled: March 20, 1998Date of Patent: July 11, 2000Assignee: Eli Lilly and CompanyInventors: Melvyn Baez, Carolyn Ann George